Latest Kaiser Health News Stories
Almost three-quarters of Americans think the pharmaceutical industry has too much power in the nation’s capital, according to the Kaiser Family Foundation.
Though opioid prescriptions appear to be on the decline, Vicodin and Norco remain popular, especially in the South. In more than half of states, Synthroid — a drug to treat hypothyroidism — came in at No. 1.
President Trump, speaking Monday, called for a tough-on-crime federal approach. Meanwhile, on Capitol Hill, legislative strategies to combat this pressing public health problem are gaining momentum, but experts are not certain these approaches will make a difference.
A nationwide shortage of injectable opioid painkillers has left hospitals scrambling to find alternatives — in some cases leading to dosage mistakes that may harm patients.
The pill, known as PrEP, can reduce the risk of contracting the virus that causes AIDS by 90 percent. Its use has expanded sharply in recent years — but primarily among a white demographic.
Purdue Pharma, whose signature product helped fuel the opioid epidemic, now wants to help treat it — or at least salvage its own reputation.
Researchers at the University of Southern California analyzed millions of prescriptions and concluded that close to a quarter paid copays that exceeded the cost of the drugs.
A new study shows that educational sessions about high blood pressure at African American barbershops, coupled with prescribing and helping to manage medication, reduced hypertension rates significantly.
KHN correspondent Shefali Luthra answered a wide variety of questions about health care in a Reddit “Ask Me Anything” chat.
California lawmakers are considering a bill that would require student health centers at all of the state’s four-year public universities to carry the abortion pill. Students at campuses across the state sounded off on the proposal.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and new podcast panelist Anna Edney of Bloomberg News discuss this week’s spate of speeches by the leaders of the Department of Health and Human Services. They also discuss the slow progress on health legislation on Capitol Hill intended to fund the government and stabilize the individual insurance market. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.
The market is flooded with 28 different medications for just 20,000 patients with the hereditary bleeding disorder. Yet intense competition hasn’t worked to bring costs down. Sales amount to $4.6 billion annually in the U.S.
A new study followed patients with severe chronic pain for a year and found that opioids relieved pain and increased function no better than common drugs like acetaminophen and lidocaine. But the opioids carry the risk of more serious side effects, including addiction and death.
Saving the lives of people with the bleeding disorder can require high doses of expensive blood-clotting factor. Taxpayers foot much of the bill as manufacturers profit enormously.
California’s health insurers trotted out a heart-healthy character with an ulterior motive — taking a dig at drugmakers.
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
Kaiser Health News Editor-in-Chief Elisabeth Rosenthal discusses drug costs with Scott Simon, the host of NPR’s Weekend Edition. Listen to the broadcast and read a transcript of that conversation.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Joanne Kenen of Politico and Margot Sanger-Katz of The New York Times discuss the health policy changes included in the just-concluded bipartisan budget deal on Capitol Hill. The panelists also talk about the final enrollment numbers for individual insurance purchased under the Affordable Care Act, and possible drug price proposals in President Donald Trump’s upcoming budget. Plus, Rovner interviews Andy Slavitt, who this week launched a health care advocacy group called “The United States of Care.”